medigraphic.com
SPANISH

Correo Científico Médico de Holguín

ISSN 1560-4381 (Print)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2018, Number 3

<< Back Next >>

Correo Científico Médico 2018; 22 (3)

Therapeutic diagnostic update of Hughes antiphospholipid syndrome

Vila BJA, Solís PQ, Medina BJ
Full text How to cite this article

Language: Spanish
References: 0
Page: 496-513
PDF size: 317.75 Kb.


Key words:

antiphospholipid syndrome, Hughes syndrome, thrombotic microangiopathy, antiphospholipid antibodies, anticardiolipins, lupus anticoagulants.

ABSTRACT

Antiphospholipid Syndrome is a disease of the immune system (thrombophilia), which is characterized by the association of antiphospholipid antibodies with recurrent thrombosis, abortions or recurrent fetal losses and thrombocytopenia. Initially described in systemic lupus erythematosus, it also appears in people who do not meet the criteria of a known disease, so its identification and treatment acquire great importance in people with apparently inexplicable thrombotic phenomena and in women with abortions and recurrent fetal deaths without other cause recognizable. Although the clinical phenomena that characterize this disease occur frequently, the incidence is low. So it is important, the identification of antiphospholipid antibodies through tests for their detection. Antiphospholipid Syndrome has no cure, but thrombotic events can be prevented by correcting the risk factors for thrombosis and using an oral anticoagulant therapy for the rest of your life.





2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Correo Científico Médico. 2018;22